PMID- 33425742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220507
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Cadherins, Selectins, and Integrins in CAM-DR in Leukemia.
PG  - 592733
LID - 10.3389/fonc.2020.592733 [doi]
LID - 592733
AB  - The interaction between leukemia cells and the bone microenvironment is known to 
      provide drug resistance in leukemia cells. This phenomenon, called cell 
      adhesion-mediated drug resistance (CAM-DR), has been demonstrated in many subsets 
      of leukemia including B- and T-acute lymphoblastic leukemia (B- and T-ALL) and 
      acute myeloid leukemia (AML). Cell adhesion molecules (CAMs) are surface 
      molecules that allow cell-cell or cell-extracellular matrix (ECM) adhesion. CAMs 
      not only recognize ligands for binding but also initiate the intracellular 
      signaling pathways that are associated with cell proliferation, survival, and 
      drug resistance upon binding to their ligands. Cadherins, selectins, and 
      integrins are well-known cell adhesion molecules that allow binding to 
      neighboring cells, ECM proteins, and soluble factors. The expression of cadherin, 
      selectin, and integrin correlates with the increased drug resistance of leukemia 
      cells. This paper will review the role of cadherins, selectins, and integrins in 
      CAM-DR and the results of clinical trials targeting these molecules.
CI  - Copyright (c) 2020 Kim, Ruan, Ogana and Kim.
FAU - Kim, Hye Na
AU  - Kim HN
AD  - Children's Hospital Los Angeles, Keck School of Medicine of University of 
      Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United 
      States.
FAU - Ruan, Yongsheng
AU  - Ruan Y
AD  - Children's Hospital Los Angeles, Keck School of Medicine of University of 
      Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United 
      States.
AD  - Department of Pediatrics, Nanfang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Ogana, Heather
AU  - Ogana H
AD  - Children's Hospital Los Angeles, Keck School of Medicine of University of 
      Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United 
      States.
FAU - Kim, Yong-Mi
AU  - Kim YM
AD  - Children's Hospital Los Angeles, Keck School of Medicine of University of 
      Southern California, Cancer and Blood Disease Institute, Los Angeles, CA, United 
      States.
LA  - eng
GR  - R01 CA172896/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20201210
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7793796
OTO - NOTNLM
OT  - bone marrow microenvironment
OT  - cell adhesion molecules
OT  - cell adhesion-mediated drug resistance
OT  - chemoresistance
OT  - leukemia
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/01/12 06:01
PMCR- 2020/01/01
CRDT- 2021/01/11 05:41
PHST- 2020/08/07 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2021/01/11 05:41 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/01/12 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.592733 [doi]
PST - epublish
SO  - Front Oncol. 2020 Dec 10;10:592733. doi: 10.3389/fonc.2020.592733. eCollection 
      2020.